IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.845
AS - Asia 1.674
EU - Europa 833
SA - Sud America 281
Continente sconosciuto - Info sul continente non disponibili 235
AF - Africa 57
OC - Oceania 4
Totale 5.929
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.754
SG - Singapore 802
CN - Cina 344
IT - Italia 228
BR - Brasile 219
HK - Hong Kong 186
VN - Vietnam 104
DE - Germania 100
RU - Federazione Russa 96
FR - Francia 90
GB - Regno Unito 60
IN - India 57
IE - Irlanda 48
FI - Finlandia 46
CA - Canada 45
KR - Corea 39
BD - Bangladesh 38
NL - Olanda 28
MX - Messico 26
UA - Ucraina 22
AR - Argentina 21
AT - Austria 20
ES - Italia 18
TR - Turchia 18
CH - Svizzera 16
TG - Togo 15
PL - Polonia 14
SE - Svezia 14
CZ - Repubblica Ceca 12
JP - Giappone 12
ID - Indonesia 11
CO - Colombia 10
PK - Pakistan 9
SA - Arabia Saudita 9
ZA - Sudafrica 9
EC - Ecuador 8
VE - Venezuela 8
IQ - Iraq 7
TN - Tunisia 7
MA - Marocco 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
KE - Kenya 5
AU - Australia 4
JM - Giamaica 4
LT - Lituania 4
NI - Nicaragua 4
PE - Perù 4
BE - Belgio 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
JO - Giordania 3
OM - Oman 3
RO - Romania 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
PR - Porto Rico 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AG - Antigua e Barbuda 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DM - Dominica 1
GP - Guadalupe 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
MT - Malta 1
MZ - Mozambico 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SX - ???statistics.table.value.countryCode.SX??? 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 5.695
Salva come PNG Salva come JPEG
Città #
Singapore 336
Ashburn 316
Council Bluffs 226
San Jose 216
Hong Kong 184
Beijing 134
Los Angeles 133
Chicago 127
Boardman 115
Fairfield 69
Chandler 68
Salt Lake City 58
Dallas 57
Lauterbourg 56
New York 48
Santa Clara 48
Dublin 47
Houston 44
Hefei 40
Munich 40
Wilmington 40
Seoul 39
Woodbridge 38
Cambridge 32
Seattle 32
Elk Grove Village 30
Ho Chi Minh City 30
Hanoi 29
Buffalo 28
Frankfurt am Main 24
Milan 24
Redondo Beach 24
Tampa 23
Helsinki 22
The Dalles 22
Montreal 21
São Paulo 20
London 17
Nuremberg 17
Phoenix 17
Zurich 16
Genoa 15
Lomé 15
Miami 15
Rome 15
Ann Arbor 14
Orem 14
Brooklyn 13
Dearborn 13
Denver 13
Pune 13
Turku 13
Vienna 13
Ogden 12
Warsaw 12
Amsterdam 11
Miano 11
Tokyo 11
Brno 10
Chennai 10
Stockholm 10
Hyderabad 9
Princeton 9
Sterling 9
Arezzo 8
Dulles 8
Lappeenranta 8
Poplar 8
Redmond 8
Shanghai 8
Detroit 7
Mumbai 7
Udine 7
Ankara 6
Atlanta 6
Brasília 6
Guangzhou 6
Jacksonville 6
Lancaster 6
Manchester 6
Mexico City 6
Naples 6
Portsmouth 6
Shenzhen 6
Toronto 6
Belluno 5
Belo Horizonte 5
Des Moines 5
Düsseldorf 5
Guarulhos 5
Guayaquil 5
Haiphong 5
Kansas City 5
Louisville 5
Madrid 5
New Delhi 5
Newark 5
Rio de Janeiro 5
Riyadh 5
San Francisco 5
Totale 3.403
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 553
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 188
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 165
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 149
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 146
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 136
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 134
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 128
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 123
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 121
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 121
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 115
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 114
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 110
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 106
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 106
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 105
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 104
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 103
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 102
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 98
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 98
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 90
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 90
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 87
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 87
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 85
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 84
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 83
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 82
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 78
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 77
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 77
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 75
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 75
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 74
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 74
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 74
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 74
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 73
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 69
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 69
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 69
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 68
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 66
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 66
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 66
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 66
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 65
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 65
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 65
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 63
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 62
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 55
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 55
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 52
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 48
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 48
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 41
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 37
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 29
DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity 22
Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence 19
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 18
A systematic literature review of economic evaluations of setmelanotide 16
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study 15
Editorial: Innovations in pharmacogenomics: embracing diversity and clinical application 14
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 13
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study 13
Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence 10
Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy 1
Totale 5.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.447
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.447
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202258 0 0 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20263.159 456 408 403 223 320 206 307 95 164 214 243 120
2026/2027457 174 177 106 0 0 0 0 0 0 0 0 0
Totale 5.929